title: The proteome signature of the inflammatory breast cancer plasma membrane identifies novel molecular markers of disease.
abstract: Inflammatory Breast Cancer (IBC) is the most lethal form of breast cancer with a 35% 5-year survival rate. The accurate and early diagnosis of IBC and the development of targeted therapy against this deadly disease remain a great medical challenge. Plasma membrane proteins (PMPs) such as E-cadherin and EGFR, play an important role in the progression of IBC. Because the critical role of PMPs in the oncogenic processes they are the perfect candidates as molecular markers and targets for cancer therapies. In the present study, Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) followed by mass spectrometry analysis was used to compare the relative expression levels of membrane proteins (MP) between non-cancerous mammary epithelial and IBC cells, MCF-10A and SUM-149, respectively. Six of the identified PMPs were validated by immunoblotting using the membrane fractions of non-IBC and IBC cell lines, compared with MCF-10A cells. Immunohistochemical analysis using IBC, invasive ductal carcinoma or normal mammary tissue samples was carried out to complete the validation method in nine of the PMPs. We identified and quantified 278 MPs, 76% of which classified as PMPs with 1.3-fold or higher change. We identified for the first time the overexpression of the novel plasminogen receptor, PLGRKT in IBC and of the carrier protein, SCAMP3. Furthermore, we describe the positive relationship between L1CAM expression and metastasis in IBC patients and the role of SCAMP3 as a tumor-related protein. Overall, the membrane proteomic signature of IBC reflects a global change in cellular organization and suggests additional strategies for cancer progression. Together, this study provides insight into the specialized IBC plasma membrane proteome with the potential to identify a number of novel therapeutic targets for IBC.
authors.affiliation: Universidad Central del Caribe-School of Medicine Bayamón, PR.
authors.forename: Ivette J
authors.initials: IJ
authors.lastname: Suárez-Arroyo
authors.affiliation: Inter American University of Puerto Rico Bayamón, PR.
authors.forename: Yismeilin R
authors.initials: YR
authors.lastname: Feliz-Mosquea
authors.affiliation: Translational Proteomics Center, University of Puerto Rico San Juan, PR.
authors.forename: Juliana
authors.initials: J
authors.lastname: Pérez-Laspiur
authors.affiliation: New York University School of Medicine, Alexandria Center for Life Sciences New York, NY, USA.
authors.forename: Rezina
authors.initials: R
authors.lastname: Arju
authors.affiliation: Department of Pathology and Laboratory Medicine, New York Methodist Hospital New York, NY, USA.
authors.forename: Shah
authors.initials: S
authors.lastname: Giashuddin
authors.affiliation: Universidad Central del Caribe-School of Medicine Bayamón, PR.
authors.forename: Gerónimo
authors.initials: G
authors.lastname: Maldonado-Martínez
authors.affiliation: Universidad Central del Caribe-School of Medicine Bayamón, PR.
authors.forename: Luis A
authors.initials: LA
authors.lastname: Cubano
authors.affiliation: New York University School of Medicine, Alexandria Center for Life Sciences New York, NY, USA.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Schneider
authors.affiliation: Universidad Central del Caribe-School of Medicine Bayamón, PR.
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Martínez-Montemayor
keywords: IBC; IDC; L1CAM; SCAMP3; SILAC; markers; membrane; proteomics